Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Sionna Therapeutics is a promising biopharmaceutical company focused on developing innovative treatments for cystic fibrosis, with potential revenue of $4.3 billion from their lead drug SION-719. While upcoming clinical data and competition from Vertex Pharmaceuticals may impact their stock, Sionna's positive outlook is supported by their pipeline programs and ongoing Phase 3 study for SION-719. However, their ultimate success will be determined by the results of their clinical trials and their ability to compete in the large CF market.

Bears say

Sionna Therapeutics is a promising company in the cystic fibrosis market, with a potential launch of their CFTR modulator targeting NBD1 in 2030. However, the risks and challenges associated with developing and commercializing rare disease treatments should not be overlooked, as well as potential competition in the market. Furthermore, any delays in the pipeline could also impact Sionna's success.

SION has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 9 analysts, SION has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.